Literature DB >> 2753335

Healing of severe perineal and cutaneous Crohn's disease with hyperbaric oxygen.

C E Brady1, B J Cooley, J C Davis.   

Abstract

Recurrent perineal Crohn's disease can be an extremely debilitating complication that may be difficult to treat. We report a patient with progressively worsening perineal and biopsy-proven cutaneous Crohn's disease that had been refractory to surgery and medical treatment (sulfasalazine, steroids, 6-mercaptopurine, metronidazole, antibiotics). As the lesions were reminiscent of problem wounds occurring in other situations, hyperbaric oxygen treatment was instituted while the patient was continued on metronidazole. Response was dramatic with almost immediate relief of symptoms and regression within 2.5 mo of wounds that had previously defied therapy for 8 yr. Clinical remission has not been sustained as four subsequent courses of hyperbaric oxygen have been given over a period of 11 mo. However, the patient has been essentially asymptomatic since her initial course and the extent of her cutaneous disease has been minimal compared with that before hyperbaric oxygen. Hyperbaric oxygen treatment is costly and should not be routinely used in every patient with perineal Crohn's disease. However, this case report may herald an advance in the understanding of the pathogenesis of this complication and ultimately, its therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2753335     DOI: 10.1016/0016-5085(89)90649-5

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  12 in total

1.  Closure of refractory perineal Crohn's lesion. Integration of hyperbaric oxygen into case management.

Authors:  E W Nelson; D E Bright; L F Villar
Journal:  Dig Dis Sci       Date:  1990-12       Impact factor: 3.199

2.  Hyperbaric oxygenation ameliorates indomethacin-induced enteropathy in rats by modulating TNF-alpha and IL-1beta production.

Authors:  Z Yang; J Nandi; J Wang; G Bosco; M Gregory; C Chung; Y Xie; X Yang; E M Camporesi
Journal:  Dig Dis Sci       Date:  2006-07-13       Impact factor: 3.199

3.  Modification of in vivo and in vitro TNF-alpha, IL-1, and IL-6 secretion by circulating monocytes during hyperbaric oxygen treatment in patients with perianal Crohn's disease.

Authors:  G Weisz; A Lavy; Y Adir; Y Melamed; D Rubin; S Eidelman; S Pollack
Journal:  J Clin Immunol       Date:  1997-03       Impact factor: 8.317

4.  Hyperbaric oxygen enhances the efficiency of 5-aminosalicylic acid in acetic acid-induced colitis in rats.

Authors:  Semih Gorgulu; Gokhan Yagci; Nihat Kaymakcioglu; Murat Ozkara; Bulent Kurt; Ayhan Ozcan; Omer Kaya; Serdar Sadir; Turgut Tufan
Journal:  Dig Dis Sci       Date:  2006-03       Impact factor: 3.199

Review 5.  The role of hyperbaric oxygen therapy in inflammatory bowel disease: a narrative review.

Authors:  Xin Wu; Tian-Yu Liang; Zhong Wang; Gang Chen
Journal:  Med Gas Res       Date:  2021 Apr-Jun

Review 6.  Anorectal Strictures in Complex Perianal CD: How to Approach?

Authors:  Amy L Lightner; Miguel Regueiro
Journal:  Clin Colon Rectal Surg       Date:  2022-01-17

7.  Hyperbaric oxygen treatment for inflammatory bowel disease: a systematic review and analysis.

Authors:  Daniel A Rossignol
Journal:  Med Gas Res       Date:  2012-03-15

8.  Combining infliximab, anti-MAP and hyperbaric oxygen therapy for resistant fistulizing Crohn's disease.

Authors:  Gaurav Agrawal; Thomas Borody; Robert Turner; Sharyn Leis; Jordana Campbell
Journal:  Future Sci OA       Date:  2015-09-28

9.  Wound healing of metastatic perineal Crohn's disease using hyperbaric oxygen therapy: A case series.

Authors:  Corine A Lansdorp; Christianne J Buskens; Krisztina B Gecse; Geert Ram D'Haens; Rob A Van Hulst
Journal:  United European Gastroenterol J       Date:  2020-06-12       Impact factor: 4.623

10.  Metastatic Crohn's disease of external genitalia.

Authors:  Charles Panackel; Joseph John; Devadas Krishnadas; Kattoor R Vinayakumar
Journal:  Indian J Dermatol       Date:  2008       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.